**Name of Journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 51571

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Impact of preoperative chemoradiotherapy using concurrent S-1 and CPT-11 on long-term clinical outcomes in locally advanced rectal cancer**

Kimura K *et al.*S-1, CPT-11, and CRT for rectal cancer

Kei Kimura, Naohito Beppu, Hiroshi Doi, Kozo Kataoka, Tomoki Yamano, Motoi Uchino, Masataka Ikeda, Hiroki Ikeuchi, Naohiro Tomita

**Kei Kimura, Naohito Beppu, Kozo Kataoka, Tomoki Yamano, Masataka Ikeda, Naohiro Tomita,** Division of Lower Gastrointestinal Surgery, Department of Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan

**Hiroshi Doi,** Department of Radiology, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan

**Hiroshi Doi,** Department of Radiation Oncology, Kindai University Faculty of Medicine, Sayama, Osaka 589-8511, Japan

**Motoi Uchino, Hiroki Ikeuchi,** Department of Inflammatory Bowel Disease, Division of Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan

**Author contributions:** All authors helped to perform the research; Kimura K manuscript writing, performing procedures and data analysis; Beppu N contributed to manuscript writing, drafting conception and design, performing experiments, and data analysis; Doi H, KataokaK, Yamano T, UchinoM, IkedaM, IkeuchiH and TomitaN contributed to writing of the manuscript.

**Corresponding author: Kei Kimura, MD, PhD, Assistant Professor,** Division of Lower Gastrointestinal Surgery, Department of Surgery, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan. k-kimura@hyo-med.ac.jp

**Received:** September 27, 2019

**Revised:** December 8, 2019

**Accepted:** December 23, 2019

**Published online:**

**Abstract**

BACKGROUND

Preoperative chemoradiotherapy regimens using a second drug for locally advanced rectal cancer are still under clinical investigation.

AIM

To investigate the clinical outcomes of patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy using tegafur/gimeracil/oteracil (S-1) plus irinotecan (CPT-11).

METHODS

This was a single-center retrospective study of 82 patients who underwent radical surgery for rectal cancer after chemoradiotherapy with S-1 (80 mg/m2/d), CPT-11 (60 mg/m2/d), and radiation (total 45 Gy) between 2009 and 2016. The median follow-up was 51 mo (range: 17–116 mo).

RESULTS

Twenty-nine patients (35.4%) had T3 or T4 rectal cancer with mesorectal fascia invasion, 36 (43.9%) had extramural vascular invasion, 24 (29.8%) had N2 rectal cancer and eight (9.8%) had lateral lymph node swelling. The relative dose intensity was 90.1% for S-1 and 92.9% for CPT-11. Seventy-nine patients (96.3%) underwent R0 resection. With regard to pathological response, 13 patients (15.9%) had a pathological complete response and 52 (63.4%) a good response (tumor regression grade 2/3). The 5-year local recurrence-free survival, relapse-free survival and overall survival rates were 90.1%, 72.5% and 91.3%, respectively. We analyzed the risk factors for local recurrence-free survival by Cox regression analysis and none were detected. Previously described risk factors such as T4 stage, mesorectal fascia invasion or lateral lymph node swelling were not detected as negative factors for local recurrence-free survival.

CONCLUSION

We demonstrated good compliance and favorable tumor regression in patients with locally advanced rectal cancer treated with preoperative S-1 and CPT-11.

**Key words:** Preoperative chemoradiotherapy; Rectal cancer; Irinotecan; Tegafur/gimeracil/oteracil; Neoadjuvant chemoradiotherapy; Radiation therapy

Kimura K, Beppu N, Doi H, Kataoka K, Yamano T, Uchino M, Ikeda M, Ikeuchi H, Tomita N. Impact of preoperative chemoradiotherapy using concurrent S-1 and CPT-11 on long-term clinical outcomes in locally advanced rectal cancer. *World J Gastrointest Oncol* 2019; In press

**Core tip:** Lower advanced rectal cancer located within 8 cm of the anal verge carries a higher risk of local recurrence. The aim of this single-center retrospective study was to assess the clinical outcomes of patients with locally advanced rectal cancer treated preoperative chemoradiotherapy using tegafur/gimeracil/oteracil plus irinotecan. Grade 3 or 4 toxicity was mild and led to good relative dose intensity with on-schedule treatment. Also, we investigated the risk factors for local recurrence-free survival and relapse-free survival.Multivariate analysis detected no factors for local recurrence-free survival. Our study confirmed good compliance and favorable tumor regression.

**INTRODUCTION**

In the 2000s, numerous studies were planned to investigate the optimal preoperative treatment strategies for advanced rectal cancer. The National Comprehensive Cancer Network and European Society for Medical Oncology consensus guidelines consider preoperative 5-fluorouracil (5-FU)-based chemoradiotherapy (CRT), 45–50.4 Gy, as standard treatment[1,2]. However, the local recurrence rate remains about 10%, and risk factors for local recurrence include T4 stage, mesorectal fascia invasion (MFI), extramural vascular invasion (EMVI) and lateral lymph node (LLN) swelling[3-6]. Multidisciplinary treatments were planned to overcome this issue, such as extended surgery, higher radiation doses, and concurrent use of second drugs, such as oxaliplatin or irinotecan (CPT-11)[7-11]. With regard to the concurrent use of second drugs, six prospective studies failed to confirm any additional benefit of oxaliplatin, and there was a significant increase in severe toxicity and an insufficient response rate[12-17]. However, several Phase II trials have demonstrated the feasibility, safety and effectiveness of CPT-11 as a second drug, with higher pathological complete response (pCR) rates[7,18-25]. *UGT1A1* polymorphisms that can be used to predict the probability of severe toxicity would be of interest for proper therapeutic management using CPT-11[26]. Therefore, the purpose of this study was to investigate the clinical outcomes of 82 patients with locally advanced rectal cancer, located 8 cm from the anal verge, treated with preoperative CRT using tegafur/gimeracil/oteracil (S-1) plus CPT-11.

**MATERIALS AND METHODS**

***Patients***

We included 82 patients with T3-4, N0-2, M0 rectal cancer located within 8 cm of the anal verge who were treated with preoperative CRT using S-1 plus CPT-11 between 2009 and 2016. Prior to preoperative therapy, all patients underwent staging work-ups that included digital rectal examination, measurement of tumor marker levels [carcinoembryonic antigen and carbohydrate antigen 19-9], chest X-ray, abdominal and pelvic computed tomography (CT) and magnetic resonance imaging (MRI). MRI was performed on two occasions, as part of initial staging and following preoperative therapy. Testing for *UGT1A1*\*6 and \*28 polymorphisms under national insurance was finally given approval in November 2008 in Japan, and it became measurable at our institution in March 2009. *UGT1A1* polymorphisms are assessed only in cases in which consent is obtained after consultation with a specialist in hereditary diseases[27]. The protocol for the present study was based on the SAMRAI-1 trial[28].

The patients were divided into two groups in accordance with the European Society for Medical Oncology guidelines to confirm the outcomes for these subgroups[29]: (1) “bad” rectal cancer [T3(b)c/T4 with peritoneal or vaginal involvement only, N1–2, MFI negative]; and (2) “ugly” rectal cancer (T4 with overgrowth to adjacent organs, pelvic side walls or sacrum, LLN positive, MFI positive).

***Preoperative CRT protocol***

Preoperative CRT consisted of S-1 (Days 1-5, 8-12, 22-26 and 29-33; 80 mg/m2/d), CPT-11 (Days 1, 8, 22 and 29; 60 mg/m2/d), and radiation (total 45 Gy, 1.8 Gy/d, 5 d per week for 5 wk). Six to eight weeks after completion of preoperative CRT, the patients were scheduled to undergo radical surgery.

***Surgical procedure and pathological assessments***

All patients underwent total mesorectal excision or extended total mesorectal excision (total mesorectal excision with adjacent visceral resection) to achieve R0 resection. The surgical procedure included low anterior resection, intersphincteric resection and abdominoperineal resection. Intersphincteric resection was recommended in accordance with tumor stage and location, patient age, and preoperative anal function, and patients who did not meet those criteria were selected for abdominoperineal resection. Diverting ileostomy was routinely constructed for all patients with intestinal continuity. LLN dissection was performed when pretreatment MRI showed that the LLNs had a short-axis diameter > 7 mm. Postoperative complications were assessed according to the Clavien-Dindo classification[30]. Pathological response to CRT was evaluated according to the Japanese Classification of Colorectal Carcinoma of the Japanese Society for Cancer of the Colon and Rectum (8th edition). Grade 0 was defined as no evidence of a therapeutic effect and Grade 3 was pCR[31]. We defined a good response as Grade 2 or 3 and poor response as Grade 0 or 1a/1b.

***Toxicity or relative dose intensity of chemotherapy***

Hematological and nonhematological toxicity caused by preoperative CRT was evaluated according to the Common Terminology Criteria for Adverse Events, version 4.0[32]. Relative dose intensity was calculated as the ratio of the actual dose to the scheduled dose; S-1 (1600 mg/m2), CPT-11 (240 mg/m2) and full irradiation dose (45 Gy). Dose reductions of CPT-11 were not applied to the group of patients with *UGT1A1* mutation.

***Patient follow-up***

Median follow-up was 51 mo (range, 17-116 mo). Postoperative adjuvant chemotherapy using 5-FU-based chemotherapy was recommended for all patients except those with ypT0/1 stage, high age, comorbidity, postoperative complications, and social factors. Patient surveillance was subsequently performed as follows: chest–abdominal CT every 6 mo, colonoscopy annually, and blood tests (including measurement of carcinoembryonic antigen and carbohydrate antigen 19-9 levels) at 3-mo intervals. Local recurrence was defined as the detection of a recurrent tumor within the pelvis, and recurrence was defined as the presence of recurrent disease outside the pelvis.

***Statistical analysis***

Local recurrence-free survival (LFS), relapse-free survival (RFS) and overall survival (OS) were estimated using the Kaplan–Meier method and compared using the log-rank test. The χ2 test was also used to evaluate associations between *UGT1A1* polymorphisms and toxicity and feasibility of treatment. We further evaluated clinical factors associated with LFS and RFS to determine the optimal clinical criteria of this regimen by Cox proportional hazard regression model. Independent variables with *P* < 0.1 in univariate analysis were entered into a multivariate analysis and *P* < 0.05 was considered statistically significant. Statistical analyses were performed using JMP version 12.0 software (SAS Japan Inc., Tokyo, Japan).

**RESULTS**

***Clinical characteristics***

The patients’ clinical characteristics are shown in Table 1. Clinical T4 stage was diagnosed in 10 patients (12.2%). Clinical N stage was deemed positive in 46 patients (56.1%). MRI revealed tumor involvement of the MF in 29 patients (35.4%). EMVI was observed in 36 patients (43.9%). According to the risk category of rectal cancer, 50 patients (61.0%) were divided into the bad group and 32 (39.0%) into the ugly group.

***Compliance and toxicity***

The relative dose intensity was 90.1% for S-1, 92.9% for CPT-11 and 97.6% for RT. Toxicity data are shown in Table 2. Grade 3 or 4 hematological toxicity consisted of leukopenia (*n* = 15; 18.3%), neutropenia (*n* = 16; 19.5%) and febrile neutropenia (*n* = 3; 3.6%). Grade 3 or 4 nonhematological toxicity consisted of diarrhea (*n* = 22; 26.8%). For Grade 3 or 4 hematological toxicity, four of 16 neutropenia patients (25.0%) whose neutrophil count was reduced to < 500 cells/μL received granulocyte colony-stimulating factor. For Grade 3 or 4 nonhematological toxicity, four of 22 diarrhea patients (18.2%) were prescribed loperamide. All patients recovered after these conservative treatments.

***UGT1A1 genotype distribution and its association with toxicity profiles***

Associations between toxicity/feasibility and *UGT1A1* polymorphisms were investigated (Table 3). Forty-eight of 82 patients (58.5%) were assessed for *UGT1A1* polymorphism, and 25 (52.1%) were wild type and 23 (47.9%) were mutant type. Patients with the mutant type had more Grade 3 or 4 hematological toxicity than those with the wild type had (*P* < 0.05). However, there was no significant difference in the incidence of nonhematological toxicity, including diarrhea, in either genotype (*P* = 0.65). There was no significant difference in CPT-11 dose intensity according to *UGT1A1* polymorphisms despite the significant differences observed in hematological toxicity (*P* = 0.26).

***Operative findings and postoperative complications***

Thirty-one patients (37.8%) underwent low anterior resection, 43 (52.4%) intersphincteric resection and eight (9.8%) abdominoperineal resection. Five patients (6.1%) underwent combined adjacent organ resection and eight (9.8%) LLN dissection.

The postoperative complications are shown in Table 4. Grade 3 pelvic infection was confirmed in nine patients (11.0%) and five (6.1%) developed Grade 3 ileus. Among the patients undergoing sphincter-preserving surgery, seven (9.5%) had Grade 3 anastomosis leakage. During follow-up, six patients could not undergo stoma takedown because of pelvic infection with anastomotic leakage (*n* = 4) and local recurrence (*n* = 2).

***Pathological findings***

Pathological findings are listed in Table 5. Thirteen patients (15.9%) achieved complete tumor regression with tumor regression grade 3 (pCR). T downstaging was seen in 41 patients (50.0%) and N downstaging in 36 (43.9%). R0 resection was performed in 79 of 82 patients (96.3%) and R1 resection in three (3.7%), with microscopic residual tumor in the anus levator muscle (*n* = 2) and pelvic plexus on the pelvic sidewall (*n* = 1). No patient had R2 resection. Patients with *UGT1A1* mutations showed a significantly better response to CRT (including CPT-11) than those without mutations (Table 3).

***Recurrence and survival***

Twenty-six patients (31.7%) received 5-FU-based adjuvant chemotherapy: UFT plus leucovorin (*n* = 19), mFOLFOX6 (*n* = 4), S-1 (*n* = 2) and capecitabine (*n* = 1). The reasons for not receiving adjuvant chemotherapy were: ypT0/1 stage (*n* = 18), high age (*n* = 11), comorbidity (*n* = 2), postoperative complications (*n* = 12), social factors (*n* = 6), and others (*n* = 7).

After a median follow-up of 51 mo, 5-year LFS, 5-year RFS and 5-year OS rates were 90.1%, 72.5% and 91.3%, respectively (Figure 1). Local recurrence was seen in six patients: LLNs (*n* = 4) and other sites (*n* = 2). Distant recurrence was detected in 20 patients: lung (*n* = 15), liver (*n* = 6), para-aortic region (*n* = 2), inguinal region (*n* = 1) and bone (*n* = 1). Some patients had overlapping metastases. LFS did not differ significantly between the bad and ugly groups (96.0% *vs* 76.2%; *P* = 0.10); however, RFS was significantly poorer in the ugly group (38.5% *vs* 87.8% in bad group; *P* < 0.01).

***Risk factors for LFS and RFS***

We investigated the risk factors for LFS and RFS (Table 6).Multivariate analysis showed that no risk factors for LFS were detected, including previously described risk factors such as T4 stage, MFI, EMVI and LLN swelling. However, MFI and EMVI were associated with poor RFS for locally advanced rectal cancer (OR: 5.82, 95%CI: 1.68-20.2, *P* < 0.01; OR: 3.42, 95%CI: 1.02-11.5, *P* = 0.04).

**DISCUSSION**

We reported the safety, effectiveness and long-term outcomes of concomitant use of CPT-11 with 5-FU-based CRT for locally advanced rectal cancer. S-1 is an oral anticancer agent containing tegafur (a prodrug of 5-FU) with two modulators, gimeracil and oteracil potassium, which markedly increase the radiosensitivity of cancer cells[33]. CPT-11 augments inhibition of thymidylate synthase – the target enzyme of 5-FU[34]. In addition, 5-FU induces topoisomerase I, and cancer cells overexpressing topoisomerase I show increased chemosensitivity to CPT-11[35]. Such *in vitro* mechanisms are effective in combination with 5-FU as a radiosensitizer for preoperative CRT[7]. Furthermore, *UGT1A1* polymorphisms that can predict the probability of developing potentially severe toxicity during treatment with CPT-11-based regimens could be clinical factors in the proper management of treatment[26]. The purpose of this study was to investigate the clinical outcomes of patients with locally advanced rectal cancer treated with preoperative CRT using S-1 plus CPT-11.

Current standard CRT regimens include only 5-FU. However, several clinical trials incorporating a second active systemic agent into conventional CRT regimens have been performed to examine the ability of the regimens to increase pCR rate and improve resectability and locoregional control[6,10]. Two such second drugs, oxaliplatin and CPT-11, have been investigated in clinical trials.

With regard to oxaliplatin, six randomized Phase III studies have compared oxaliplatin-based with 5-FU-based regimens[12-17]. Among these, the STAR-01 (16% both groups), ACCORD 12/0405 (19% *vs* 14%), NSABP R-04 (21% *vs* 19%) and PETACC-6 (15% *vs* 13%) studies reported that there were no substantial improvements in pCR rates, and significantly increased intolerable Grade 3 or 4 toxicity. For this reason, the concomitant use of oxaliplatin in 5-FU-based CRT has not been permitted (Supplementary Table 1). No Phase III studies using CPT-11 have been documented; however, nine Phase II studies (2 randomized controlled trials and 7 single-arm studies) have assessed the usefulness of CPT-11 as a radiosensitizer[7,18-25]. These studies indicated that this CPT-based regimen was promising in terms of pCR rate (range 13.7%-37%). Grade 3 or 4 toxicity was mild and led to good relative dose intensity with on-schedule treatment without dose reduction (Supplementary Table 2).

The most frequent severe toxicity was neutropenia (2.1%-12%) and diarrhea (2.1%-22%). Generally, toxicity was correlated with the dose of chemotherapy. Jung *et al*[25], who used 40 mg/m2 CPT-11, demonstrated that the rate of Grade 3 or 4 hematological toxicity was 1.4% and the rate of Grade 3 or 4 nonhematological toxicity was 5.7%. Sato *et al*[7], who used 80 mg/m2 CPT-11, demonstrated that the rate of Grade 3 or 4 hematological toxicity was 6% and the rate of Grade 3 or 4 nonhematological toxicity was 4.5%. These results suggest that concurrent use of second drugs, such as CPT-11 as a radiosensitizer, is well tolerated in terms of toxicity.

*UGT1A1* polymorphisms have been confirmed as predictive markers of severe toxicity of CPT-11 in a metastatic setting[26]. Our previous study demonstrated the effectiveness of *UGT1A1* polymorphism in predicting the toxicity of preoperative CRT using CPT-11, although it was only a small retrospective study[36]. Thus, to provide patients with the full benefit of CRT, good tolerance of CPT-11-based regimens for patients with *UGT1A1* mutant type, as well as the prevention and early treatment of severe toxicity, is important. This suggests that drawing definitive conclusions about the role of *UGT1A1* polymorphisms requires a randomized trial, to assess whether genotype-adjusted dose of CPT-11 would help establish a well-tolerated, effective dose for tumor response in patients with wild-type and mutant *UGT1A1*.

The present study included patients with highly advanced rectal cancer: 29 (35.4%) with T4 or T3 with MFI, 36 (43.9%) with EMVI, 24 (29.8%) with N2, and 32 (39.0%) with ugly rectal cancer. Even such highly advanced rectal cancer demonstrated favorable local control. With respect to systemic recurrence, highly advanced rectal cancer has a high recurrence rate, with poor prognosis; therefore, combined use of systemic treatment, mainly including chemotherapy, is important for prolonging survival benefit[37]. Further studies are warranted to examine the additional effect of CPT-11 on those tumors.

Our study had several limitations. First, it was a small retrospective study performed in a single institution. Second, we excluded atypical rectal cancer, such as mucinous carcinoma caused by anal fistula, which is associated with a poorer response to CRT, because we chose surgery without radiation. Third, we excluded patients with performance status 3/4 or those aged > 80 years who cannot tolerate this regimen owing to comorbidity and old age. Such patients (*n* = 3) were treated with stoma creation alone. Fourth, the follow-up time was not sufficient to evaluate OS, LFS and RFS. Fifth, *UGT1A1* polymorphism analysis was not performed for all patients receiving preoperative CRT. Finally, we did not study toxicity-based dose-finding methods for S-1 plus CPT-11 preoperative CRT in a Phase I study. Nevertheless, this study demonstrated the safety, effectiveness and long-term oncological outcomes of locally advanced rectal cancer treated with concomitant CPT-11 and 5-FU-based CRT.

In conclusion, our single-center retrospective study confirmed good compliance, favorable tumor regression and feasible oncological outcomes of preoperative CRT using S-1 plus CPT-11, and favorable local control of highly advanced rectal cancer by this regimen.

**ARTICLE HIGHLIGHTS**

***Research background***

Prospective studies have investigated the optimal treatment strategies for management of locally advanced rectal cancer, and have concluded that preoperative 5-fluorouracil-based chemoradiotherapy (CRT) at 45–50.4 Gy is a standard treatment. However, local recurrence rate remains about 10%; mainly for highly advanced cases.

***Research motivation***

Multidisciplinary treatments were planned to overcome highly advanced rectal cancer, such as extended surgery, higher radiation doses, and concurrent use of second drugs, such as oxaliplatin or CPT-11.

***Research objectives***

The aim of this study was to investigate the safety, therapeutic effect, and outcome of preoperative CRT using S-1 plus irinotecan for locally advanced lower rectal cancer.

***Research methods***

Between 2009 and 2016, 82 patients underwent total mesorectal excision after preoperative CRT. Preoperative CRT consisted of S-1 (80 mg/m2/d), CPT-11 (60 mg/m2/d), and radiation (total 45 Gy). The median follow-up was 51 months (range: 17-116 mo).

***Research results***

This regimen was well tolerated in terms of toxicity. Associations between toxicity/feasibility and *UGT1A1* polymorphisms were investigated. Compared with patients with wild-type *UGT1A1*, those with mutant typehad more Grade 3 or 4 hematological toxicity (*P* < 0.05). With regard to oncological outcome, mesorectal fascia invasion and extramural vascular invasion were associated with poor relapse-free survival for locally advanced rectal cancer. However, Cox regression analysis did not detect any risk factors for local recurrence-free survival.

***Research conclusions***

This regimen had favorable oncological outcomes for highly advanced rectal cancer***.***

***Research perspectives***

This was a small retrospective study performed in a single institution. A randomized multicenter study is needed to investigate the influence of dose setting by *UGT1A1* polymorphism for preoperative CRT using irinotecan.

**REFERENCES**

1 **Sauer R**, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, Becker H, Raab HR, Villanueva MT, Witzigmann H, Wittekind C, Beissbarth T, Rödel C. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. *J Clin Oncol* 2012; **30**: 1926-1933 [PMID: 22529255 DOI: 10.1200/JCO.2011.40.1836]

2 **Park JH**, Yoon SM, Yu CS, Kim JH, Kim TW, Kim JC. Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer. *Cancer* 2011; **117**: 3703-3712 [PMID: 21328328 DOI: 10.1002/cncr.25943]

3 **Glimelius B**, Holm T, Blomqvist L. Chemotherapy in addition to preoperative radiotherapy in locally advanced rectal cancer - a systematic overview. *Rev Recent Clin Trials* 2008; **3**: 204-211 [PMID: 18782078 DOI: 10.2174/157488708785700294]

4 **Taylor FG**, Quirke P, Heald RJ, Moran BJ, Blomqvist L, Swift IR, Sebag-Montefiore D, Tekkis P, Brown G; Magnetic Resonance Imaging in Rectal Cancer European Equivalence Study Study Group. Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study. *J Clin Oncol* 2014; **32**: 34-43 [PMID: 24276776 DOI: 10.1200/JCO.2012.45.3258]

5 **Smith NJ**, Barbachano Y, Norman AR, Swift RI, Abulafi AM, Brown G. Prognostic significance of magnetic resonance imaging-detected extramural vascular invasion in rectal cancer. *Br J Surg* 2008; **95**: 229-236 [PMID: 17932879 DOI: 10.1002/bjs.5917]

6 **Kusters M**, Slater A, Muirhead R, Hompes R, Guy RJ, Jones OM, George BD, Lindsey I, Mortensen NJ, Cunningham C. What To Do With Lateral Nodal Disease in Low Locally Advanced Rectal Cancer? A Call for Further Reflection and Research. *Dis Colon Rectum* 2017; **60**: 577-585 [PMID: 28481851 DOI: 10.1097/DCR.0000000000000834]

7 **Sato T**, Ozawa H, Hatate K, Onosato W, Naito M, Nakamura T, Ihara A, Koizumi W, Hayakawa K, Okayasu I, Yamashita K, Watanabe M. A Phase II trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus irinotecan and radiation in patients with locally advanced rectal cancer: clinical feasibility and response rate. *Int J Radiat Oncol Biol Phys* 2011; **79**: 677-683 [PMID: 21035953 DOI: 10.1016/j.ijrobp.2009.11.007]

8 **Fujita S**, Mizusawa J, Kanemitsu Y, Ito M, Kinugasa Y, Komori K, Ohue M, Ota M, Akazai Y, Shiozawa M, Yamaguchi T, Bandou H, Katsumata K, Murata K, Akagi Y, Takiguchi N, Saida Y, Nakamura K, Fukuda H, Akasu T, Moriya Y; Colorectal Cancer Study Group of Japan Clinical Oncology Group. Mesorectal Excision With or Without Lateral Lymph Node Dissection for Clinical Stage II/III Lower Rectal Cancer (JCOG0212): A Multicenter, Randomized Controlled, Noninferiority Trial. *Ann Surg* 2017; **266**: 201-207 [PMID: 28288057 DOI: 10.1097/SLA.0000000000002212]

9 **Kusters M**, Beets GL, van de Velde CJ, Beets-Tan RG, Marijnen CA, Rutten HJ, Putter H, Moriya Y. A comparison between the treatment of low rectal cancer in Japan and the Netherlands, focusing on the patterns of local recurrence. *Ann Surg* 2009; **249**: 229-235 [PMID: 19212175 DOI: 10.1097/SLA.0b013e318190a664]

10 **Mohiuddin M**, Regine WF, John WJ, Hagihara PF, McGrath PC, Kenady DE, Marks G. Preoperative chemoradiation in fixed distal rectal cancer: dose time factors for pathological complete response. *Int J Radiat Oncol Biol Phys* 2000; **46**: 883-888 [PMID: 10705009 DOI: 10.1016/s0360-3016(99)00486-1]

11 **Yang YJ**, Cao L, Li ZW, Zhao L, Wu HF, Yue D, Yang JL, Zhou ZR, Liu SX. Fluorouracil-based neoadjuvant chemoradiotherapy with or without oxaliplatin for treatment of locally advanced rectal cancer: An updated systematic review and meta-analysis. *Oncotarget* 2016; **7**: 45513-45524 [PMID: 27322422 DOI: 10.18632/oncotarget.9995]

12 **Gérard JP**, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne PL, Vendrely V, François E, de La Roche G, Bouché O, Mirabel X, Denis B, Mineur L, Berdah JF, Mahé MA, Bécouarn Y, Dupuis O, Lledo G, Montoto-Grillot C, Conroy T. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. *J Clin Oncol* 2010; **28**: 1638-1644 [PMID: 20194850 DOI: 10.1200/JCO.2009.25.8376]

13 **O'Connell MJ**, Colangelo LH, Beart RW, Petrelli NJ, Allegra CJ, Sharif S, Pitot HC, Shields AF, Landry JC, Ryan DP, Parda DS, Mohiuddin M, Arora A, Evans LS, Bahary N, Soori GS, Eakle J, Robertson JM, Moore DF Jr, Mullane MR, Marchello BT, Ward PJ, Wozniak TF, Roh MS, Yothers G, Wolmark N. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. *J Clin Oncol* 2014; **32**: 1927-1934 [PMID: 24799484 DOI: 10.1200/JCO.2013.53.7753]

14 **Aschele C**, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, Artale S, Tagliagambe A, Ambrosini G, Rosetti P, Bonetti A, Negru ME, Tronconi MC, Luppi G, Silvano G, Corsi DC, Bochicchio AM, Chiaulon G, Gallo M, Boni L. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. *J Clin Oncol* 2011; **29**: 2773-2780 [PMID: 21606427 DOI: 10.1200/JCO.2010.34.4911]

15 **Rödel C**, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, Hofheinz RD, Ghadimi M, Wolff HA, Lang-Welzenbach M, Raab HR, Wittekind C, Ströbel P, Staib L, Wilhelm M, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R, Liersch T; German Rectal Cancer Study Group. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol* 2015; **16**: 979-989 [PMID: 26189067 DOI: 10.1016/S1470-2045(15)00159-X]

16 **Deng Y**, Chi P, Lan P, Wang L, Chen W, Cui L, Chen D, Cao J, Wei H, Peng X, Huang Z, Cai G, Zhao R, Huang Z, Xu L, Zhou H, Wei Y, Zhang H, Zheng J, Huang Y, Zhou Z, Cai Y, Kang L, Huang M, Peng J, Ren D, Wang J. Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial. *J Clin Oncol* 2016; **34**: 3300-3307 [PMID: 27480145 DOI: 10.1200/JCO.2016.66.6198]

17 **Schmoll HJ,** Haustermans K, Price T, Stein A, Nordlinger B, Hofheinz R, Jean-Francois D, Brenner B, Schmidt P, Reinel H, Hollerbach S, Caca K, Fauth F, J, Hannig C, Zalcberg J-R, Tebbutt N, Mauer M, Messina C, Lutz M. Van Cutsem E. Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: Disease-free survival results at interim analysis. *J Clin Oncol* 2014; **32**: 3501 [DOI: 10.1200/jco.2014.32.15\_suppl.3501]

18 **Mehta VK**, Cho C, Ford JM, Jambalos C, Poen J, Koong A, Lin A, Bastidas JA, Young H, Dunphy EP, Fisher G. Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. *Int J Radiat Oncol Biol Phys* 2003; **55**: 132-137 [PMID: 12504045 DOI: 10.1016/s0360-3016(02)03863-4]

19 **Navarro M**, Dotor E, Rivera F, Sánchez-Rovira P, Vega-Villegas ME, Cervantes A, García JL, Gallén M, Aranda E. A Phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer. *Int J Radiat Oncol Biol Phys* 2006; **66**: 201-205 [PMID: 16814947 DOI: 10.1016/j.ijrobp.2006.04.007]

20 **Willeke F**, Horisberger K, Kraus-Tiefenbacher U, Wenz F, Leitner A, Hochhaus A, Grobholz R, Willer A, Kähler G, Post S, Hofheinz RD. A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer. *Br J Cancer* 2007; **96**: 912-917 [PMID: 17325705 DOI: 10.1038/sj.bjc.6603645]

21 **Shin SJ**, Kim NK, Keum KC, Kim HG, Im JS, Choi HJ, Baik SH, Choen JH, Jeung HC, Rha SY, Roh JK, Chung HC, Ahn JB. Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer. *Radiother Oncol* 2010; **95**: 303-307 [PMID: 20211505 DOI: 10.1016/j.radonc.2010.02.003]

22 **Hong YS**, Kim DY, Lim SB, Choi HS, Jeong SY, Jeong JY, Sohn DK, Kim DH, Chang HJ, Park JG, Jung KH. Preoperative chemoradiation with irinotecan and capecitabine in patients with locally advanced resectable rectal cancer: long-term results of a Phase II study. *Int J Radiat Oncol Biol Phys* 2011; **79**: 1171-1178 [PMID: 20605355 DOI: 10.1016/j.ijrobp.2009.12.073]

23 **Gollins S**, Sun Myint A, Haylock B, Wise M, Saunders M, Neupane R, Essapen S, Samuel L, Dougal M, Lloyd A, Morris J, Topham C, Susnerwala S. Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: impact on long-term clinical outcomes. *J Clin Oncol* 2011; **29**: 1042-1049 [PMID: 21263095 DOI: 10.1200/JCO.2010.29.7697]

24 **Wong SJ**, Winter K, Meropol NJ, Anne PR, Kachnic L, Rashid A, Watson JC, Mitchell E, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG. Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer. *Int J Radiat Oncol Biol Phys* 2012; **82**: 1367-1375 [PMID: 21775070 DOI: 10.1016/j.ijrobp.2011.05.027]

25 **Jung M**, Shin SJ, Koom WS, Jung I, Keum KC, Hur H, Min BS, Baik SH, Kim NK, Kim H, Lim JS, Hong SP, Kim TI, Roh JK, Park YS, Ahn JB. A Randomized Phase 2 Study of Neoadjuvant Chemoradiaton Therapy With 5-Fluorouracil/Leucovorin or Irinotecan/S-1 in Patients With Locally Advanced Rectal Cancer. *Int J Radiat Oncol Biol Phys* 2015; **93**: 1015-1022 [PMID: 26581140 DOI: 10.1016/j.ijrobp.2015.08.037]

26 **Miyata Y**, Touyama T, Kusumi T, Morita Y, Mizunuma N, Taniguchi F, Manabe M. UDP-glucuronosyltransferase 1A1\*6 and \*28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer. *Int J Clin Oncol* 2016; **21**: 696-703 [PMID: 26710796 DOI: 10.1007/s10147-015-0937-x]

27 **Kawato Y**, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. *Cancer Res* 1991; **51**: 4187-4191 [PMID: 1651156]

28 **Sato T**, Hayakawa K, Tomita N, Noda M, Kamikonya N, Watanabe T, Kato D, Sakai Y, Hiraoka M, Shimada M, Ikushima H, Baba H, Oya N, Oya M, Nemoto-Murofushi K, Takeuchi M, Watanabe M. A multicenter phase I study of preoperative chemoradiotherapy with S-1 and irinotecan for locally advanced lower rectal cancer (SAMRAI-1). *Radiother Oncol* 2016; **120**: 222-227 [PMID: 27317556 DOI: 10.1016/j.radonc.2016.06.002]

29 **Blomqvist L**, Glimelius B. The 'good', the 'bad', and the 'ugly' rectal cancers. *Acta Oncol* 2008; **47**: 5-8 [PMID: 18097776 DOI: 10.1080/02841860701802585]

30 **Dindo D**, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg* 2004; **240**: 205-213 [PMID: 15273542 DOI: 10.1097/01.sla.0000133083.54934.ae]

31 **Japanese Society for Cancer of the Colon and Rectum.** General rules for clinical and pathological studies on cancer of the colon, rectum, and anus. 8th ed. Tokyo: Kanehara & Co., 2013

32 **U.S. Department of Health and Human Sciences,** National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE\_4.03\_2010-06-14\_QuickReference\_5x7.pdf

33 **Nakata E**, Fukushima M, Takai Y, Nemoto K, Ogawa Y, Nomiya T, Nakamura Y, Milas L, Yamada S. S-1, an oral fluoropyrimidine, enhances radiation response of DLD-1/FU human colon cancer xenografts resistant to 5-FU. *Oncol Rep* 2006; **16**: 465-471 [PMID: 16865244 DOI: 10.3892/or.16.3.465]

34 **Guichard S**, Hennebelle I, Bugat R, Canal P. Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line. *Biochem Pharmacol* 1998; **55**: 667-676 [PMID: 9515577 DOI: 10.1016/s0006-2952(97)00541-8]

35 **Saltz LB**, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. *N Engl J Med* 2000; **343**: 905-914 [PMID: 11006366 DOI: 10.1056/NEJM200009283431302]

36 **Kimura K**, Yamano T, Igeta M, Imada A, Jihyung S, Babaya A, Hamanaka M, Kobayashi M, Tsukamoto K, Noda M, Ikeda M, Tomita N. UGT1A1 polymorphisms in rectal cancer associated with the efficacy and toxicity of preoperative chemoradiotherapy using irinotecan. *Cancer Sci* 2018; **109**: 3934-3942 [PMID: 30246377 DOI: 10.1111/cas.13807]

37 **Brændengen M**, Glimelius B. Preoperative radiotherapy or chemoradiotherapy in rectal cancer - Is survival improved? An update of the "Nordic" LARC study in non-resectable cancers. *Radiother Oncol* 2018; **127**: 392-395 [PMID: 29778486 DOI: 10.1016/j.radonc.2018.05.004]

**Footnotes**

**Institutional review board statement:** The protocol was approved by the Institutional Review Board at Hyogo College of Medicine, Japan (No.2756).

**Informed consent statement:** Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.

**Conflict-of-interest statement:** All authors declare no conflicts-of-interest related to this article.

**Data sharing statement:** No additional data are available.

**Open-Access:** This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** September 27, 2019

**First decision:** October 18, 2019

**Article in press:**

**Specialty type:** Oncology

**Country of origin:** Japan

**Peer-review report classification**

Grade A (Excellent): A

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Gu GL, Pan ZZ **S-Editor:** Dou Y **L-Editor:** **E-Editor:**

**Figure Legends**

**Figure 1 Long-term outcomes of patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy using tegafur/gimeracil/oteracil plus irinotecan.**

**Table 1 Patient characteristics**

|  |  |
| --- | --- |
| **Characteristic** | ***n* = 82** |
| Age (yr) |  |
| Median (range) | 64 (34–79) |
| Sex |  |
| Male | 60 (73.2) |
| Female | 22 (26.8) |
| Distance from anal verge (cm) |  |
| Median (range) | 5.0 (0–8) |
| Size of tumor (cm) |  |
| Median (range) | 4.5 (2–9) |
| Clinical T stage (before chemoradiotherapy) |  |
| 3 | 72 (87.8) |
| 4 | 10 (12.2) |
| Mesorectal fascia invasion |  |
| − | 53 (64.6) |
| + | 29 (35.4) |
| Extramural vascular invasion |  |
| − | 46 (56.1) |
| + | 36 (43.9) |
| Clinical N stage (before chemoradiotherapy) |  |
| − | 36 (43.9) |
| + | 46 (56.1) |
| Subgroup of locally advanced rectal cancer |  |
| Bad | 50 (61.0) |
| Ugly | 32 (39.0) |
| *UGT1A1* polymorphism (in 48 patients) |  |
| Wild type | 25 (52.1) |
| Mutant type | 23 (47.9) |

Data are *n* (%) unless otherwise shown.

**Table 2 Acute toxicity according to Common Terminology Criteria for Adverse Events 4.0, on patients receiving chemoradiotherapy, *n* (%)**

|  |  |
| --- | --- |
| **Toxicity** | ***n* = 82** |
| **Any Grade** | **Grade 3 or 4** |
| Hematological toxicity |
| Neutropenia  | 56 (68.3) | 16 (19.5) |
| Leukopenia | 59 (72.0) | 15 (18.3) |
| Febrile neutropenia | 3 (3.6) | 3 (3.6) |
| Thrombocytopenia | 11 (13.4) | 0 |
| Nonhematological toxicity |
| Diarrhea | 53 (64.6) | 22 (26.8) |
| Anorexia | 20 (24.4) | 1 (1.2) |
| Fatigue  | 15 (18.3) | 0 |
| Nausea | 13 (15.9) | 0 |

**Table 3 Associations between toxicity, feasibility and treatment effect and *UGT1A1* polymorphisms, *n* (%)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | **Wild type (*n* = 25)** | **Mutant type (*n* = 23)** | ***P* value** |
| Toxicity |
|  | Hematological toxicity (Grade 3 or 4) | 0 | 11 (47.8) | < 0.01 |
|  | Nonhematological toxicity (Grade 3 or 4) | 8 (32.0) | 6 (26.1) | 0.65 |
| Feasibility (%) |
|  | S-1 dose intensity (mean ± SD) | 90.9 ± 0.2 | 89.0 ± 0.2 | 0.38 |
|  | CPT-11 dose intensity (mean ± SD) | 93.0 ± 0.3 | 88.2 ± 0.2 | 0.26 |
| Treatment effect |
|  | Good response  | 18 (72.0) | 22 (95.7) | < 0.01 |
|  | Poor response | 7 (28.0) | 1 (4.3) |
|  | Pathological complete response | 5 (20.0) | 6 (26.1) | 0.61 |

CPT-11: Irinotecan; S-1: Tegafur/gimeracil/oteraci.

**Table 4 Postoperative surgical complications, *n* (%)**

|  |  |
| --- | --- |
| **Complication** | ***n* = 82** |
| **Any grade** | **Grade 3** |
| Pelvic infection  | 15 (18.3) | 9 (11.0) |
| Anastomosis leakage1 | 9 (12.2) | 7 (9.5) |
| Ileus | 11 (13.4) | 5 (6.1) |
| Bleeding | 1 (1.2) | 1 (1.2) |
| Surgical site infection | 2 (2.4) | 0 |
| Urinary dysfunction | 8 (9.8) | 0 |
| Venous thromboembolic event | 1 (1.2) | 0 |
| Re-operation | 0 | 0 |

1The patients who performed abdominoperineal resection was excluded, and anastomosis leakage rates were calculated. SSI: Surgical site infection; VTE: Venous thromboembolic event.

**Table 5** **Pathological tumor characteristics, *n* (%)**

|  |  |
| --- | --- |
| **Pathological tumor characteristics** | ***n* = 82** |
| ypT stage |  |
| 0 | 13 (15.9) |
| 1 | 5 (6.1) |
| 2 | 21 (25.6) |
| 3 | 25 (42.7) |
| 4 | 8 (9.8) |
| ypN stage |  |
| − | 65 (79.3) |
| + | 17 (20.7) |
| yp TNM stage 1 |  |
| 0 | 13 (15.9) |
| I | 20 (24.4) |
| II | 32 (39.0) |
| III | 17 (20.7) |
| Residual tumor classification |  |
| R0 | 79 (96.3) |
| R1 | 3 (3.7) |
| R2 | 0 |
| Histology |  |
| well/moderately differentiated | 66 (80.5) |
| Poorly differentiated/mucinous/signet | 16 (19.5) |
| T downstaging |  |
| − | 41 (50.0) |
| + | 41 (50.0) |
| N downstaging |  |
| − | 46 (56.1) |
| + | 36 (43.9) |
| Tumor regression grade |  |
| 1a | 18 (22.0) |
| 1b | 12 (14.6) |
| 2 | 39 (47.6) |
| 3 | 13 (15.9) |
| Adjuvant chemotherapy |  |
| – | 56 (68.3) |
| + | 26 (31.7) |

1According to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. R0: No residual tumor confirmed microscopically; R1: Microscopic tumor residue; R2: Macroscopic tumor residue.

**Table 6** **Multivariate prognostic analysis for local recurrence-free survival and relapse-free survival**

|  |  |  |  |
| --- | --- | --- | --- |
| **Factors** | ***n*** | **LFS** | **RFS** |
| **Univariate** | **Multivariate** | **Univariate** | **Multivariate** |
| **OR** | **95%CI** | ***P* value** | **OR** | **95%CI** | ***P* value** | **OR** | **95%CI** | ***P* value** | **OR** | **95%CI** | ***P* value** |
| Sex |
| Female | 22 |  |  |  |  |  |  |  |  |  |  |  |  |
| Male | 60 | 1.91 | 0.21-17.7 | 0.56 |  |  |  | 1.13 | 0.36-3.60 | 0.83 |  |  |  |
| Location from anal verge (cm) |
| ≥ 5.0 | 29 |  |  |  |  |  |  |  |  |  |  |  |  |
| < 5.0 | 53 | 1.10 | 0.19-6.41 | 0.91 |  |  |  | 1.89 | 0.61-5.89 | 0.26 |  |  |  |
| Tumor diameter (cm) |
| < 4.5 | 42 |  |  |  |  |  |  |  |  |  |  |  |  |
| ≥ 4.5 | 40 | 2.00 | 0.86-2.89 | 0.43 |  |  |  | 0.63 | 0.22-1.74 | 0.37 |  |  |  |
| cT |
| 3 | 72 |  |  |  |  |  |  |  |  |  |  |  |  |
| 4 | 10 | 4.25 | 0.67-27.0 | 0.10 | 1.97 | 0.23-17.1 | 0.54 | 3.80 | 0.97-14.9 | 0.06 | 2.05 | 0.39-10.7 | 0.39 |
| cN |
| − | 36 |  |  |  |  |  |  |  |  |  |  |  |  |
| ＋ | 46 | 1.62 | 0.28-9.38 | 0.59 |  |  |  | 1.25 | 0.34-2.60 | 0.90 |  |  |  |
| Mesorectal fascia invasion |
| − | 53 |  |  |  |  |  |  |  |  |  |  |  |  |
| ＋ | 29 | 4.08 | 0.70-23.8 | 0.10 | 2.88 | 0.39-21.5 | 0.30 | 7.31 | 2.39-22.4 | < 0.01 | 5.82 | 1.68-20.2 | < 0.01 |
| Extramural vascular invasion |
| − | 46 |  |  |  |  |  |  |  |  |  |  |  |  |
| ＋ | 36 | 2.75 | 0.47-15.9 | 0.24 |  |  |  | 3.15 | 1.10-9.03 | 0.03 | 3.42 | 1.02-11.5 | 0.04 |
| Lateral lymph node (> 7.0 mm) |
| − | 74 |  |  |  |  |  |  |  |  |  |  |  |  |
| ＋ | 8 | 5.83 | 0.88-38.7 | 0.09 | 4.71 | 0.65-34.2. | 0.12 | 2.01 | 0.44-9.29 | 0.36 |  |  |  |
| Histology |
| well/moderately differentiated | 66 |  |  |  |  |  |  |  |  |  |  |  |  |
| poorly differentiated/mucinous/signet | 16 | 0.81 | 0.09-7.49 | 0.86 |  |  |  | 1.55 | 0.46-7.58 | 5.15 |  |  |  |

CI: Confidence interval; LFS: Local recurrence-free survival; OR: Odds ratio, RFS: Relapse-free survival.